D-0097-2018 Class III Terminated
FDA drug recall D-0097-2018 was initiated by Lupin Pharmaceuticals Inc. on Nov 21, 2017 and is designated Class III. Reason for recall: Failed Dissolution Specification The recall status is terminated (terminated Apr 15, 2019). Affected quantity: 111,648 units.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 6, 2017
- Initiation Date
- Nov 21, 2017
- Termination Date
- Apr 15, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 111,648 units
Product description
Duloxetine Delayed-Release Capsules USP, 30 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Goa 403 722 India, NDC 68180-295-06, UPC 368180295068
Reason for recall
Failed Dissolution Specification
Distribution pattern
Nationwide within the United States
Code information
Lot #: G602051, Exp. 12/2017
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0097-2018
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026